State Street Corp Orchard Therapeutics PLC Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.42 - $0.78 $412 - $765	-981 Reduced 0.88%	110,366 $64,000
Q1 2022 May 16, 2022	BUY	$0.7 - $1.51 $3,433 - $7,406	4,905 Added 4.61%	111,347 $79,000
Q4 2021 Feb 14, 2022	SELL	$1.16 - $2.23 $65,546 - $126,008	-56,506 Reduced 34.68%	106,442 $141,000
Q3 2021 Nov 15, 2021	BUY	$2.24 - $4.29 $134,659 - $257,897	60,116 Added 58.46%	162,948 $375,000
Q2 2021 Aug 16, 2021	SELL	$4.39 - $7.23 $473,716 - $780,174	-107,908 Reduced 51.2%	102,832 $451,000
Q1 2021 May 17, 2021	BUY	$4.39 - $9.08 $54,536 - $112,800	12,423 Added 6.26%	210,740 $1.53 Million
Q4 2020 Feb 16, 2021	BUY	$3.86 - $5.07 $103,332 - $135,723	26,770 Added 15.61%	198,317 $857,000
Q3 2020 Nov 10, 2020	SELL	$4.11 - $6.45 $123,554 - $193,899	-30,062 Reduced 14.91%	171,547 $705,000
Q2 2020 Aug 14, 2020	BUY	$5.75 - $11.99 $722,832 - $1.51 Million	125,710 Added 165.63%	201,609 $1.21 Million
Q1 2020 May 11, 2020	BUY	$5.65 - $15.71 $428,829 - $1.19 Million	75,899 New	75,899 $572,000

545K

Ticker ORTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,458,000
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.